Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by canadapieton Jan 12, 2023 9:45am
176 Views
Post# 35218106

RE:Too many things can go right at these price levels

RE:Too many things can go right at these price levels
"Sale they made in panic"........LOL

What you write (and others.....) reads as a humorous narration!!!
Sellers didn't sell in panic, but in the knowledge the company did not deliver what was promised!!! It took way to long trough the fase 1 to see some efficacy and their "key" element that wasn't there....????!!!!. I won't write an essay anymore on all the things that went wrong (or at least not in the wright direction)....
And "At these price levels it qualifies as a stupid buy......" , stupid yes, thought out is another thing...!!!! Is the price really cheap for a company with no money, no partners, no insiders buying?????
Good luck with you're investment!!! (i am "in" other biotechs now, just a little TH left in one port. Will rebuy when insiders do.)

Too many things can go right at these price levels
Given the many possible good surpises that can occur, may it be Nash combo partnership with Big Pharma given renewed interest in the Nash drugs or Trogarzo companion opportunity with Gilead new drug.  Also any kind of life out of the Sort-1 platform will stir the soul of shareholders.  Until then we have growing sales from legacy drugs and the sales structure is pretty decent now.  At these price levels it qualifies as a stupid buy whatever the doom sayers will come up with to justify their frustrations or the sale they made in panic.
<< Previous
Bullboard Posts
Next >>